Blincyto Adverse Event Report 2018


This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions


Blincyto is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Blincyto is used to treat a certain type of acute lymphoblastic leukemia in adults and children. Blincyto is given after other cancer treatments have been tried without success. Blincyto was approved by the US Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, some people responded to this medicine, but further studies are needed. Blincyto may also be used for purposes not listed in this medication guide.